Aspen sells Ovestin Europe rights for EUR 197 million; AVID matches A$2.24 billion Ingenia offer
Rallies · · AI-summarised by FinFlash
Monday's deal flow included Aspen Pharmacare selling European rights to Ovestin to Ennogen Healthcare for 197 million euros, or $220 million, and AVID matching an A$2.24 billion proposal for Australia's Ingenia Communities. Public Policy Holding agreed to buy Reevemark for up to $80 million. Mitsubishi also agreed to sell a 49.9% interest in a holding company that owns its LNG Canada stake to Blackstone funds for about Mid-sized deals point to steady M&A appetite outside the AI megadeals. Watch Ingenia's board response for a possible Australian bidding contest. Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.So What?
Understand the context